

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

**LUPUS CORA 2021 Program**

*\*The congress will take place in Central European Summer Time (CEST)*

**Wednesday, 6 October 2021**

<b>Hall 1</b>		
CEST (UTC+2 Paris, Amsterdam, Berlin) 11:15–12:15 hours / EDT (UTC-4 New York, Montreal) 5:15 – 6:15 hours / CST (UTC+8 Beijing, Manila, Perth) 17:15 – 18:15 hours		
<b>Industry Symposium</b>		<b>SEMI LIVE</b>
CEST (UTC+2 Paris, Amsterdam, Berlin) 12:15–13:45 hours / EDT (UTC-4 New York, Montreal) 6:15 – 7:45 hours / CST (UTC+8 Beijing, Manila, Perth) 18:15 – 19:45 hours		
<p><b>Opening Ceremony &amp; Keynote Lecture</b>                  Welcome to LUPUS 2021                  Welcome to CORA 2021                  Top Abstract Awards presentation  <b>Keynote lecture</b>                  Chairs: Andrea Doria (Italy), Marta Mosca (Italy), Marcello Govoni (Italy)  <b>How the discovery of antiphospholipid antibodies has changed lupus life</b>                  Angela Tincani (Italy)                  Award presentation: Andrea Doria, Yehuda Shoenfeld, Angela Tincani</p>		
Short break		
CEST (UTC+2 Paris, Amsterdam, Berlin) 14:00–16:00 hours / EDT (UTC-4 New York, Montreal) 8:00 – 10:00 hours / CST (UTC+8 Beijing, Manila, Perth) 20:00 – 22:00 hours		
<p><b>Parallel 1 SLE</b>  <b>Pathogenic insights and implications for treatment</b>                  Chairs: Carlo Chizzolini (Switzerland), Lindsey Criswell (USA)                  1. BAFF in systemic lupus erythematosus. Carlo Chizzolini (Switzerland)                  2. New insights into the role of B lineage cells in SLE. Thomas Dörner (Germany)                  3. What we are learning from single cell analyses of renal myeloid cells in lupus nephritis – from mouse to human. Anne Davidson (USA)</p>	<p><b>Parallel 2 SLE</b>  <b>Disease activity and outcome measures in SLE</b>                  Chairs: Eric Morand (Australia), Ian Bruce; UK                  1. New Insights into Activity, Organ Damage and Co-Morbidity of SLE. M Petri (USA)                  2. New perspective in measuring disease activity and in defining T2T goals. L Sousa-Inês (PT)                  3. The patient’s view in the disease assessment. Chiara Tani (IT)                  4. DOES EXPERT OPINION MATCH THE DEFINITIONS OF LOW DISEASE ACTIVITY STATE? PROSPECTIVE ANALYSIS</p>	<p><b>Parallel 3 SLE</b>  <b>NeuroSLE</b>                  Chairs: M Govoni (IT), DT Boumpas (GR)                  1. Neuroimaging as a biomarker in NPSLE. A Bortoluzzi (IT)                  2. Neuropathogenic autoantibodies in SLE. B Diamond (USA)                  3. Vagus Nerve Stimulation Reduces Pain and Fatigue in Patients with SLE. C Aranow (USA)                  4. THE IMPACT OF REMISSION AND LOW DISEASE ACTIVITY ATTAINMENT ON HEALTH-RELATED QUALITY</p>

## Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>4. GENE SIGNATURE FINGERPRINTS DIVIDE SLE PATIENTS IN SUBGROUPS WITH SIMILAR BIOLOGICAL DISEASE PROFILES: A MULTICENTER LONGITUDINAL STUDY. Javad Wahadat (Netherlands)</p> <p>5. ASSOCIATIONS BETWEEN EARLY CHANGES IN CIRCULATING B CELL SUBSETS AND SEVERE FLARE IN SYSTEMIC LUPUS ERYTHEMATOSUS – RESULTS FROM THREE PHASE III TRIALS OF BELIMUMAB. Ioannis Parodis (Sweden)</p>	<p>OF 500 PATIENTS FROM A SPANISH MULTICENTER COHORT. Irene Altabás González (Spain)</p> <p>5. ASSESSING THE IMPACT OF PHYSICIAN GLOBAL ASSESSMENT ON DORIS REMISSION RATES IN SLE - ANALYSIS FROM A GERMAN SLE-COHORT. Johanna Mucke (Germany)</p>	<p>OF LIFE IN TWO PHASE III CLINICAL TRIALS OF BELIMUMAB IN SLE. Shahrzad Kia Komujuni (Sweden)</p> <p>5. AUTOANTIBODY-INDUCED DISRUPTION OF SPATIAL ENCODING AS A BIOMARKER FOR NEUROPSYCHIATRIC LUPUS. Patricio T. Huerta (United States of America)</p> <p>6. NEUROPSYCHIATRIC INVOLVEMENT IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE UK JSLE COHORT STUDY. Teresa Giani (Italy)</p>
<p>CEST (UTC+2 Paris, Amsterdam, Berlin) 16:00–16:30 hours / EDT (UTC-4 New York, Montreal) 10:00 – 10:30 hours / CST (UTC+8 Beijing, Manila, Perth) 22:00 – 22:30 hours</p>		
<p>Networking break</p>		
<p>CEST (UTC+2 Paris, Amsterdam, Berlin) 16:30–18:00 hours / EDT (UTC-4 New York, Montreal) 10:30 – 12:00 hours / CST (UTC+8 Beijing, Manila, Perth) 22:30 – 24:00 hours</p>		
<p><b>Plenary 1: When should we use the new drugs in lupus nephritis?</b></p> <p>Chair: Andrea Doria, Italy</p> <p>Introduction: Andrea Doria, Italy</p> <p>Voclosporin: Brad H Rovin (USA)</p> <p>Belimumab: F Houssiau, Brussels (BE)</p> <p>Obinutuzumab: Richard Furie (USA)</p> <p>Panel discussion: Brad H Rovin (USA), F Houssiau (BE), R Furie (USA), Maria Dall’Era (USA), T M Chan (Hong Kong), D Jayne (UK), HJ Anders (DE)</p> <p>Summary: Andrea Doria (Italy)</p>		
<p>Short break</p>		
<p>CEST (UTC+2 Paris, Amsterdam, Berlin) 18:15–19:15 hours / EDT (UTC-4 New York, Montreal) 12:15 – 13:15 hours / CST (UTC+8 Beijing, Manila, Perth) 00:15 – 01:50 hours</p>		
<p><b>Industry Symposium</b></p>		

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

**Thursday, 7 October 2021**

Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
CEST (UTC+2 Paris, Amsterdam, Berlin) 08:00–09:00 hours / EDT (UTC-4 New York, Montreal) 2:00 – 3:00 hours / CST (UTC+8 Beijing, Manila, Perth) 14:00 – 15:00 hours				
<b>Meet the Professor 1</b> <b>Biologics in SLE:</b> Josef Smolen (Austria) 	<b>Meet the Professor 2</b> <b>Comorbidities and SLE:</b> Sandra Navarra (Philippines) 	<b>Workshop 1</b> <b>Lupus nephritis</b> F Houssiau (Belgium) 	<b>Workshop 2</b> <b>Cutaneous lupus lesions</b> A Kuhn (Germany) 	<b>Meet the Professor (CORA) 1</b> <b>Jak-inhibitors in rheumatoid arthritis</b> Ernest Choy (UK) 
CEST (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours / EDT (UTC-4 New York, Montreal) 3:00 – 4:30 hours / CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours				
<b>Plenary 2: Antimalarials are useful but rather weak medications for SLE</b> Chair: Eric Morand (Australia) Introduction: Eric Morand (Australia) Yes, it is true. Ronald F. van Vollenhoven, The Netherlands Vs. No, it is not true. Nathalie Costedoat-Chalumeau, France Panel discussion Summary: Eric Morand (Australia) 				
CEST (UTC+2 Paris, Amsterdam, Berlin) 10:30–11:00 hours / EDT (UTC-4 New York, Montreal) 4:30 – 5:00 hours / CST (UTC+8 Beijing, Manila, Perth) 16:30 – 17:00 hours				
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions				
LIVE E-POSTER DISCUSSION: SLE 01 Chair: Mandana Nikpour (Australia) 	LIVE E-POSTER DISCUSSION: SLE 02 Chair: Mariele Gatto (Italy) 	LIVE E-POSTER DISCUSSION: SLE 03 Chair: Margherita Zen (Italy) 	LIVE E-POSTER DISCUSSION: CORA 01 Chair: Alessandro Giollo (Italy) 	
CEST (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00 hours / EDT (UTC-4 New York, Montreal) 5:00 – 7:00 hours / CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours				
<b>Parallel 4 SLE</b> <b>Arthritis, vaccines, and COVID-19 in SLE</b> Chairs: L Czirjak (HU), S Navarra (The Philippines) 1. Predicting erosive arthritis in SLE. Fabrizio Conti (Italy) 2. Vaccination in SLE. CC Mok (Hong Kong) 3. Poor prognosis of COVID-19 ARDS in SLE. E Bonfá (Brazil) 4. GLUCOCORTICOIDS AND B CELL DEPLETING AGENTS SUBSTANTIALLY IMPAIR IMMUNOGENICITY OF MRNA	<b>Parallel 1 (CORA)</b> <b>Autoimmunity and autoinflammation</b> Chair: Maurizio Cutolo (Italy) Introduction: Maurizio Cutolo (Italy) Can Silicone breast implant be considered safe? YES: Franco Bassetto, (Italy) NO: Yehuda Shoenfeld, (Israel) Panel Discussino & Poll 1. EFFECTS OF THE PARATHORMONE RECEPTOR EXPRESSION ON B CELLS AND	<b>Parallel 2 (CORA)</b> <b>Systemic sclerosis</b> Chair: R Giacomelli (Italy) Introduction: R. Giacomelli Is it possible to determine which patients benefit most from nintedanib and which from immunosuppressants in SSc-ILD? YES: M Matucci Cerinic (Italy) NO: Y Allanore (France) Panel Discussion & Poll		

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>VACCINES TO SARS-COV-2. Alfred H. Kim (United States of America)</p> <p>5. COVID-19 PROGNOSIS IS WORSE IN MALE COMPARED TO FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE CONTROL-19 STUDY BY THE ITALIAN SOCIETY OF RHEUMATOLOGY. Chiara Scirocco (Italy)</p> <p style="text-align: right;"><b>SEMI LIVE</b></p>	<p>THE BIOLOGICAL EFFECTS OF THE HORMONE ON CELL FUNCTIONING IN AUTOIMMUNE DISEASES. Gabriel J. Tobón (Colombia)</p> <p>2. CHANGES IN CIRCULATING B CELL LEVELS AND IMMUNOPHENOTYPE ARE ASSOCIATED WITH DEVELOPMENT OF ARTHRITIS FOLLOWING TREATMENT WITH CHECKPOINT INHIBITORS. MARIELE GATTO (Italy)</p> <p>3. EVALUATION OF EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKERS OF MYOSITIS. CHIARA FRANCO (Italy)</p> <p style="text-align: right;"><b>SEMI LIVE</b> </p>	<p>1. CHANGES OF ANTI-TOPOISOMERASE-1 ANTIBODY IN PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE AS A PREDICTOR OF BETTER RESPONSE ON RITUXIMAB TREATMENT. Liudmila Garzanova (Russian Federation)</p> <p>2. THE IMPACT OF CYCLOPHOSPHAMIDE (CYP) AND RITUXIMAB (RTM) ON SYSTEMIC SCLEROSIS (SSC) CLINICAL MANIFESTATION P AND THE SAFETY OF THESE AGENTS. Olga Koneva (Russian Federation)</p> <p>3. IDENTIFICATION OF SIGNS FOR EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Natalia Yudkina (Russian Federation)</p> <p style="text-align: right;"><b>SEMI LIVE</b> </p>
---	---	--

CEST (UTC+2 Paris, Amsterdam, Berlin) 13:00–14:15 hours / EDT (UTC-4 New York, Montreal) 7:00 – 8:00 hours / CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours



<p>13:15-14:15</p> <p>Networking Break, Exhibition &amp; Poster Viewing + Short Oral Discussions</p>	<p>13:00-14:15</p> <p><b>Industry Symposium</b></p> <p style="text-align: right;"><b>SEMI LIVE</b></p>
<p>Hall 2</p> <p>LIVE E-POSTER DISCUSSION: SLE 04</p> <p>Chair: Luca Iaccarino (Italy)</p> <p style="text-align: right;"></p>	
<p>Hall 3</p> <p>LIVE E-POSTER DISCUSSION: SLE 05</p> <p>Chair: Raquel Faria (Portugal)</p> <p style="text-align: right;"></p>	
<p>Hall 4</p> <p>LIVE E-POSTER DISCUSSION: SLE 06</p> <p>Chair: Ioannis Parodis (Sweden)</p> <p style="text-align: right;"></p>	
<p>Hall 5</p> <p>LIVE E-POSTER DISCUSSION: CORA 02</p> <p>Chair: Roberta Ramonda (Italy)</p> <p style="text-align: right;"></p>	

CEST (UTC+2 Paris, Amsterdam, Berlin) 14:15–15:45 hours / EDT (UTC-4 New York, Montreal) 8:15 – 9:45 hours / CST (UTC+8 Beijing, Manila, Perth) 20:15 – 21:45 hours

<p><b>Plenary 3: How common is clinical remission in the real life? Experience from all around the world</b></p> <p>Chair: R Van Vollenhoven (The Netherlands)</p> <p>Introduction: R. Van Vollenhoven (The Netherlands)</p> <p>Italy: Andrea Doria, The Netherlands: AE. Voskuijl, USA: M Petri, Latin America: MF Ugarte-Gil, Real life experiences from Hong Kong: CC Mok, Asia-Pacific: M Nikpour</p>
---

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

Panel discussion and summary: A Doria, AE. Voskuilj, M Petri, MF Ugarte Gill, CC Mok, M Nikpour Summary: R van Vollenhoven (The Netherlands) 					
CEST (UTC+2 Paris, Amsterdam, Berlin) 15:45–16:15 hours / EDT (UTC-4 New York, Montreal) 9:45 – 10:15 hours / CST (UTC+8 Beijing, Manila, Perth) 21:45 – 22:15 hours					
Industry Symposium 		Industry Symposium 			
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:15–16:45 hours / EDT (UTC-4 New York, Montreal) 10:15 – 10:45 hours / CST (UTC+8 Beijing, Manila, Perth) 22:15 – 22:45 hours					
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions					
LIVE E-POSTER DISCUSSION: SLE 07 Chair: Liliana Saraiva (Portugal) 	LIVE E-POSTER DISCUSSION: SLE 08 Chair: Diogo Jesus (Portugal) 	LIVE E-POSTER DISCUSSION: CORA 03 Chair: Paolo Sfriso (Italy) 			
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:45–18:45 hours / EDT (UTC-4 New York, Montreal) 10:45 – 12:45 hours / CST (UTC+8 Beijing, Manila, Perth) 22:45 – 00:45 hours					
<b>Parallel 5 SLE</b> <b>Precision and personalized Medicine</b> Chairs: G. Bertsias (Greece); Chaim Putterman (US) 1. Stratification of Lupus and Systemic Autoimmune Diseases: Clinical Utility. Marta Alarcón Riquelme (Spain) 2. How far away is precision medicine for SLE? Joan Merrill (USA) 3. How close are we to personalised medicine for SLE? Ian Bruce (UK) 4. PERSONALIZED MOLECULAR PORTRAITS OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AS KEY FOR PROGNOSIS AND THERAPEUTIC DECISIONS. Daniel Toro-Domínguez (Spain) 5. DIFFERENTIAL GENE EXPRESSION OF	<b>Parallel 6 SLE</b> <b>Cardiovascular (and vascular) risk management</b> Chairs: A. Rahman (UK), D Wallace (USA) 1. Cardiovascular disease in SLE: the contribution of lupus associated risk factors. E Svenungsson (SE) 2. [New] EULAR Recommendations for cardiovascular risk management in SLE and APS. M Tektonidou (Greece) 3. Thrombosis in systemic lupus erythematosus. J Sanchez-Guerrero (Canada) 4. SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) AND CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL COHORT STUDY. Chi Chiu Mok (Hong Kong PRC)	<b>Parallel 7 SLE</b> <b>Early SLE</b> Chairs: M. Urowitz (Canada); L. Sousa-Inês (Portugal) 1. Early lupus manifestations: when UCTD become SLE. Marta Mosca (Italy) 2. The Winding Road to Lupus: How can some avoid the destination? Judith James (USA) 3. Systemic lupus, big data & digital medicine: where do we stand? L Arnaud (France) 4. ANALYSIS OF GLUCOCORTICOID USE IN NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS (GULP): RESULTS FROM THE ITALIAN MULTICENTER INCEPTION COHORT OF THE EARLY LUPUS PROJECT. ELISABETTA CHESSA (Italy) 5. ANA POSITIVITY IS ASSOCIATED WITH COMPLEX IMMUNE	<b>Parallel 3 (CORA)</b> <b>Rheumatoid arthritis</b> Chair: C Montecucco (Italy) Does RA seropositivity counts in disease and therapeutic outcome? YES: seropositive and seronegative patients are different, respond to different therapies, have different clinical manifestations, even genetics Josef Smolen, (Austria) NO: they are the same Roberto Caporali, (Italy) Panel Discussion & Poll 1. AUTOANTIBODIES TO PROTEIN-ARGININE DEIMINASE (PAD) 1 FROM THE SERA OF RHEUMATOIR ARTHRITIS (RA) PATIENTS RECOGNIZE THEIR ANTIGEN INDEPENDENTLY OF ITS	<b>Parallel 4 (CORA)</b> <b>Systemic sclerosis 2</b> Chair: G Szucs (Hungary) Can we always distinguish PAH (group I) from group 3 PH in SSc patients? YES: Elisabetta Zanatta (Italy) No: Cosimo Bruni, (Italy) Panel Discussion & Poll 1. FREQUENCY OF DISEASE PROGRESSION AFTER IMMUNOSUPPRESSIVE WITHDRAWAL IN A RETROSPECTIVE COHORT OF SYSTEMIC SCLEROSIS PATENTS. Francesco Benvenuti (Italy) 2. EPIDEMIOLOGY OF IDIOPATHIC INFLAMMATORY MYOPATHIES IN AFRICA: A CONTEMPORARY SYSTEMATIC REVIEW. Mickael Essouma (Cameroon)	

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>GLYCOSYLATION-RELATED PROTEINS IN SLE PATIENTS FROM THE PRECISESADS COHORT. László Kovács (Hungary)</p> <p>6. APPLICATION OF CLUSTER ANALYSIS TO IDENTIFY DISEASE PHENOTYPE ASSOCIATED WITH EROSIIVE ARTHRITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Francesco Natalucci (Italy)</p> <p style="text-align: right;"><b>SEMI LIVE</b></p>	<p>5. CONTRIBUTION OF COMORBIDITIES TO ACCUMULATED DAMAGE IN SLE. ARGENTINE REGISTRY OF SYSTEMIC LUPUS ERYTHEMATOSUS. Verónica I. Bellomio (Argentina)</p> <p>6. ASSESSMENT OF MYOCARDIAL FIBROSIS USING ADVANCED ECHOCARDIOGRAPHY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PILOT STUDY. Alessandro Giollo (Italy)</p> <p style="text-align: right;"><b>SEMI LIVE</b></p>	<p>DISTURBANCE EVEN IN INDIVIDUALS WHO DO NOT DEVELOP CLINICAL AUTOIMMUNE DISEASE. Sabih Ul Hassan (United Kingdom)</p> <p>6. CLINICAL FACTORS ASSOCIATED WITH FOCAL NECROTIZING GLOMERULAR LESIONS IN PATIENTS WITH LUPUS NEPHRITIS. Vladimir Dobronravov (Russian Federation)</p> <p style="text-align: right;"><b>SEMI LIVE</b></p>	<p>AUTOCITRULLINATION STATUS. Laura Martinez-Prat (Spain)</p> <p>2. AUTOANTIBODIES TO PROTEIN-ARGININE DEIMINASE (PAD) 1 FROM THE SERA OF RHEUMATOIR ARTHRITIS (RA) PATIENTS RECOGNIZE THEIR ANTIGEN INDEPENDENTLY OF ITS AUTOCITRULLINATION STATUS. Laura Martinez-Prat (Spain)</p> <p style="text-align: right;"><b>SEMI LIVE</b> </p>	<p>3. DIAGNOSTIC PERFORMANCE OF THE ACR/EULAR 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A ROUTINE CARE SETTING. María Teresa Schiaffino (Spain)</p> <p style="text-align: right;"><b>SEMI LIVE</b> </p>
---	---	--	---	---

CEST (UTC+2 Paris, Amsterdam, Berlin) 18:45–19:45 hours / EDT (UTC-4 New York, Montreal) 12:45 – 13:45 hours / CST (UTC+8 Beijing, Manila, Perth) 00:45 – 01:45 hours

<p><b>Meet the Professor 3</b> <b>Biologics in SLE</b> Americas: J Merrill (USA)</p> <p style="text-align: right;"></p>	<p><b>Meet the Professor 4</b> <b>The standard of care in SLE</b> Americas: M. Urowitz (Canada)</p> <p style="text-align: right;"> </p>	<p><b>Workshop 3</b> <b>Lupus nephritis</b> Americas: M Dall’Era (USA)</p> <p style="text-align: right;"></p>	<p><b>Workshop 4</b> <b>Cutaneous lupus lesions</b> Americas: VP Werth (USA)</p> <p style="text-align: right;"></p>	<p><b>Meet the professor (CORA) 2</b> <b>Autoinflammatory diseases</b> Paolo Sfriso (Italy)</p> <p style="text-align: right;"></p>
--	---	--	--	---

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

**Friday, 8 October 2021**

Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
CEST (UTC+2 Paris, Amsterdam, Berlin) 08:00–09:00 hours / EDT (UTC-4 New York, Montreal) 2:00 AM – 3:00 AM / CST (UTC+8 Beijing, Manila, Perth) 14:00 – 15:00 hours				
<p><b>Meet the Professor 5</b>  <b>Molecules in the development in SLE therapy</b>                      R. Van Vollenhoven (The Netherlands)</p> <p></p>	<p><b>Meet the Professor 6</b>  <b>Unmet needs in SLE: how do we assess it?</b>                      E Morand (Australia)</p> <p></p>	<p><b>Workshop 5</b>  <b>Anti-Rheumatic treatment before and during pregnancy</b>                      R Fischer-Betz (Germany) and Isabell Haase (Germany)</p> <p> </p>	<p><b>Workshop 6</b>  <b>Cardio-pulmonary manifestations</b>                      D. D’Cruz (UK)</p> <p></p>	<p>Late Breaking Abstracts 2021                      Chair: Alessandro Giollo (Italy)</p> <p>FOLLICULAR TH-SUBSETS IN HASHIMOTO’S THYROIDITIS ASSOCIATED WITH PSYCHIATRIC DISORDERS. Polina A. Sobolevskaia (Russian Federation)</p> <p>AN INFLUENCE OF ANTI-THYROPEROXIDASE ANTIBODIES ON THE EXPRESSION OF MCL 1 IN MURINE PLACENTAS                      Elena Borodina (Russian Federation)</p> <p>INTERLEUKIN-35 IN ANKYLOSING SPONDYLITIS: ASSOCIATION WITH DISEASE ACTIVITY AND RADIOGRAPHIC PROGRESSION. Anna Abou-Raya (Egypt)</p> <p>RETINAL VASCULAR DENSITY IN ANCA-ASSOCIATED VASCULITIDES: A FIRST EVIDENCE FROM A SINGLE-CENTER STUDY. Paola Triggianese (Italy)</p> <p></p>
CEST (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours / EDT (UTC-4 New York, Montreal) 3:00 – 4:30 hours / CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours				
<p><b>Plenary 4</b>  <b>The time has come to set up diagnostic criteria in SLE?</b>                      Chair: M Mosca (Italy)</p>				

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>Introduction: M. Mosca                  Yes: G Bertias (Greece) Vs.                  No: M Aringer (Germany)                  Panel discussion &amp; Poll                  Summary: M Mosca (Italy)</p>	
--	---

CEST (UTC+2 Paris, Amsterdam, Berlin) 10:30–11:00 hours / EDT (UTC-4 New York, Montreal) 4:30 – 5:00 hours / CST (UTC+8 Beijing, Manila, Perth) 16:30 – 17:00 hours

Networking Break, Exhibition & Poster Viewing + Short Oral Discussions

	LIVE E-POSTER DISCUSSION: SLE 10 Chair: Anna Abou-Raya (Egypt) 	LIVE E-POSTER DISCUSSION: SLE 11 Chair: Zahi Touma (Canada) 	LIVE E-POSTER DISCUSSION: CORA 04 Chair: Augusta ortolan (Italy) 
--	---	--	--

CEST (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00 hours / EDT (UTC-4 New York, Montreal) 5:00 – 7:00 hours / CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours

<p><b>Parallel 8 SLE</b>  <b>Antiphospholipid antibody syndrome and SLE</b>                  Chairs: Y Shoenfeld (Israel), R Cervera (Spain)                  Antiphospholipid antibodies and damage in SLE: the changing paradigm. G Ruiz-Irastorza (Spain)                  Long term follow-up of APS patients. N Agmon-Levin (Israel)                  Peptide therapies for antiphospholipid syndrome. A Rahman (UK)                  LOW PRECONCEPTION COMPLEMENT IS ASSOCIATED WITH ADVERSE PREGNANCY OUTCOMES: A MULTICENTER STUDY OF 260 PREGNANCIES IN 197 WOMEN WITH ANTIPHOSPHOLIPID SYNDROME OR ANTIPHOSPHOLIPID ANTIBODIES CARRIERS. Daniele Lini (Italy)</p>	<p><b>LUPUS Academy Session</b>                  Chairs: A. Doria (Italy), E. Bonfá (Brazil)                  Case 1: Lupus Podocytopathy Sandra Navarra (Philippines)                  Case 2: Polyarthritis in a Young Woman R Van Vollenhoven (Netherlands)                  Case 3: Disease Activity/ Remission D. Isenberg (UK)                  Case 4: Lupus Diagnosis Eloisa Bonfá (Brazil)</p>	<p><b>Parallel 5 (CORA)</b>  <b>Spondylarthritis</b>                  Chair: Roberta Ramonda (Italy)                  Did the understanding and treatment of non-radiographic axSpA add anything to our management of spondylarthritis? YES: nr-axSpA gave a new view new drugs etc Xenophon Baraliakos, (Germany)                  NO: we did not learn anything advanced axSpA is the same Dennis McGonagle, (UK)                  Panel Discussion &amp; Poll                  COULD SKIN PSORIASIS INFLUENCE RADIOGRAPHIC SPINAL AND PELVIC PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS? RESULTS FROM THE ITALIAN ARM OF SPONDYLOARTHRITIS-CAUGHT-EARLY (SPACE) STUDY DURING 48-MONTHS FOLLOW-UP. Mariagrazia Lorenzin (Italy)</p>	<p><b>Parallel 6 (CORA)</b>  <b>COVID/Vaccination</b>                  Chair: Howard Amital (Israel)                  Can patients with AIDs be vaccinated and when? Marc Bijl, (The Netherlands)                  Different types of COVID vaccinations: are they all the same? Pier Luigi Meroni (Italy)                  Post COVID/vaccination syndrome: is it a reality? Michael Ehrenfeld (Israel)                  ASSOCIATION BETWEEN ENVIRONMENTAL AIR POLLUTION AND OSTEOPOROSIS, A POPULATION-BASED COHORT ANALYSIS. Giovanni Adami (Italy)                  ARTHRITIS FLARES AFTER COVID-19 VACCINATION. Kam H. Hon YOON (Singapore)                  HUMORAL RESPONSE TO PFIZER MRNA VACCINE AGAINST SARS COV2, IN CONNECTIVE TISSUE DISEASE PATIENTS AND THE IMPACT ON THE RHEUMATIC DISEASE ACTIVITY. Yolanda Braun-Moscovici (Israel)</p>
---	---	---	---

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>INCREASED RISK OF MORTALITY AND CANCER IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LUPUS COHORT FROM 1998 TO 2015. Ga Young Ahn (Korea, Republic of)</p> <p>PERSISTENT ANTIPHOSPHOLIPID ANTIBODY AND ITS SUBGROUPS HINDER PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM REACHING TARGET: A PROPENSITY-SCORE MATCHED REAL-WORLD STUDY. Huijuan Zhang (China)</p> <p>SEMI LIVE</p>	<p>THE GENETIC CONTRIBUTION TO DRUG RESPONSE IN SPONDYLOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW. Giacomo Cozzi (Italy)</p> <p>ENTHESITIS AND ITS RELATIONSHIP WITH DISEASE ACTIVITY, FUNCTIONAL STATUS, AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS. Lyubov D. Vorobyeva (Russian Federation)</p> <p>SEMI LIVE VOTE</p>	<p>SEMI LIVE</p>
---	--	------------------

CEST (UTC+2 Paris, Amsterdam, Berlin) 13:00–14:15 hours / EDT (UTC-4 New York, Montreal) 7:00 – 8:00 hours / CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours

<p>13:15-14:15</p> <p>Networking Break, Exhibition &amp; Poster Viewing + Short Oral Discussions</p>	<p>13:00-14:15</p> <p><b>Industry Symposium</b></p> <p>SEMI LIVE</p>
<p>Hall 2</p> <p>LIVE E-POSTER DISCUSSION: SLE 12</p> <p>Chair: Matteo Piga (Italy)</p> <p></p>	
<p>Hall 3</p> <p>LIVE E-POSTER DISCUSSION: SLE 13</p> <p>Chair: Johanna Mucke (Germany)</p> <p></p>	
<p>Hall 4</p> <p>LIVE E-POSTER DISCUSSION: SLE 14</p> <p>Chair: Nancy Agmon-Levin (Israel)</p> <p></p>	
<p>Hall 5</p> <p>LIVE E-POSTER DISCUSSION: CORA 05</p> <p>Chair: Ljudmila Stojanovich (Serbia)</p> <p></p>	

CEST (UTC+2 Paris, Amsterdam, Berlin) 14:15–16:15 hours / EDT (UTC-4 New York, Montreal) 8:15 – 10:15 hours / CST (UTC+8 Beijing, Manila, Perth) 20:15 – 22:15 hours

<p><b>Parallel 9 SLE: Biomarkers</b></p> <p>Chairs: Dimitrios Bogdanos (Greece), J Buyon (USA)</p>	<p><b>Parallel 10 SLE: Pipeline molecules in SLE</b></p> <p>Chairs: David Wofsy (USA), R Van Vollenhoven (The Netherlands)</p> <p>Overview of the 2021 pipeline molecules in SLE. Richard Furie (USA)</p>	<p><b>Parallel 11 SLE: Lupus nephritis – clinical aspects</b></p> <p>Chairs: F. Houssiau (Belgium), BH Rovin (USA)</p>
--	---	--

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>Clinical and Multiomics Studies of SLE. Sang-Cheol Bae (South Korea) Useful biomarkers for early diagnosis of SLE. C Putterman (USA) Biomarkers for lupus nephritis. R Cervera, (Spain) DYSREGULATED ENDOTHELIAL MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Sandy Bergkamp (Netherlands) RELATIONSHIP BETWEEN RETINAL MICROVASCULAR ALTERATIONS ASSESSED BY OCT-ANGIOGRAPHY AND KIDNEY INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: A PILOT STUDY. Sara Ferrigno (Italy) <b>SEMI LIVE</b></p>	<p>Baricitinib. Yoshiya Tanaka, (Japan) CD40/CD40L in SLE. Josef Smolen (Austria) BIIB059 DEMONSTRATES IMPROVEMENT IN JOINT MANIFESTATIONS IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE PHASE 2 LILAC PART A STUDY. Ronald F. Van Vollenhoven (Netherlands) BARICITINIB REDUCES PROINFLAMMATORY SERUM CYTOKINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Thomas Dörner (Germany) M5049, A NOVEL TOLL-LIKE RECEPTOR 7 AND 8 INHIBITOR AS ORAL THERAPY FOR LUPUS PATIENTS: FROM DISCOVERY TO PHASE 1B DOSE SELECTION. Torsten Witte (Germany)</p>	<p>New Approvals and New Guidelines on Lupus Nephritis – Clarity or Confusion? Tak Mao Chan (Hong Kong) Clinical and histological features able to predict long term lupus nephritis prognosis. Gabriella Moroni, (Italy) Lupus nephritis = chronic kidney disease: implications for management. Hans-Joachim Anders (Germany) What is remission and what does it mean in terms of longer-term clinical benefit? David Jayne, (UK)</p>				
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:15–16:45 hours / EDT (UTC-4 New York, Montreal) 10:15 – 10:45 hours / CST (UTC+8 Beijing, Manila, Perth) 22:15 – 22:45 hours						
<b>Industry Symposium SEMI LIVE</b>						
CEST (UTC+2 Paris, Amsterdam, Berlin) 16:45–17:15 hours / EDT (UTC-4 New York, Montreal) 10:45 – 11:15 hours / CST (UTC+8 Beijing, Manila, Perth) 22:45 – 23:15 hours						
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions						
<p>LIVE E-POSTER DISCUSSION: SLE 15 Chair: Marcello Govoni (Italy) <b>LIVE!</b></p>	<p>LIVE E-POSTER DISCUSSION: SLE 16 Chair: Chiara Tani (Italy) <b>LIVE!</b></p>	<p>LIVE E-POSTER DISCUSSION: CORA 06 Chair: Roberto Padoan (Italy) <b>LIVE!</b></p>				
CEST (UTC+2 Paris, Amsterdam, Berlin) 17:15–19:15 hours / EDT (UTC-4 New York, Montreal) 11:15 – 13:15 hours / CST (UTC+8 Beijing, Manila, Perth) 23:15 – 01:15 hours						
<p><b>Parallel 12 SLE: New clues in SLE pathogenesis</b> Chairs: Z Amoura (FR), G Tsokos (USA) The epigenetic contribution to SLE. Lindsey Criswell (USA) The role of the interferon system in SLE. L Rönnblom (Sweden)</p>	<p><b>Parallel 13 SLE: How do we integrate available biologics in SoC?</b> Chairs: J Smolen (AT), R. Furie (USA) 10 years of belimumab (2011-2021): what have we learned so far? L Iaccarino (Italy)</p>	<p><b>Parallel 14 SLE: Skin</b> Chairs: E Bonfá (BR) G Girolomoni, (IT) The tamed wolf ...! Management of refractory cutaneous lupus erythematosus. A Kuhn (Germany) Translational studies in CLE and CLE/SLE. V Werth (USA)</p>	<p><b>Parallel 7 (CORA): COVID/Vaccination</b> Chair: A Iagnocco (IT) Is post-COVID syndrome an autoimmune disease? YES: Yehuda Shoenfeld, (Israel) NO: Agostino Riva, (Italy)</p>	<p><b>Parallel 8 (CORA): Sjögren syndrome</b> Chair: R Gerli (IT) Is salivary gland biopsy mandatory in Sjögren Syndrome? YES: Thomas Dörner, (Germany) NO: A.G. Tzioufas, (Greece)</p>		

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>The role of bone marrow in the pathogenesis of SLE. DT Boumpas (Greece)</p> <p>COMPLEMENT C4 COPY NUMBER VARIATION IS ASSOCIATED WITH ANTI-RO/SSA AND ANTI-LA/SSB AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. Christian Lundtoft (Sweden)</p> <p>MOLECULAR SUBTYPES, AUTOANTIBODIES PROFILES, GENDER AND GENETICS INFLUENCE THE EPIGENOME OF SYSTEMIC LUPUS ERYTHEMATOSUS. Elena C. Carnero-Montoro (Spain)</p> <p>DISEASE-CAUSING GENE VARIANTS ACCOUNT FOR A MINIMUM OF 5.5% OF JUVENILE-ONSET SLE PATIENTS IN THE UK. Amandine Charras (United Kingdom)</p>	<p>B cell depletion works in SLE: how we should correctly deliver it. D Isenberg (UK)</p> <p>IFN blockade in SLE: where are we now, and what does the future hold? E. Morand (Australia)</p> <p>EARLY RISK OF INFECTION IN SLE PATIENTS TREATED WITH RITUXIMAB: RESULTS FROM THE BILAG-BIOLOGICS REGISTER. Sarah Dyball (United Kingdom)</p> <p>PHARMACODYNAMIC EFFECTS ON IMMUNOGLOBULINS FOLLOWING DAPIROLIZUMAB PEGOL TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. Christian Stach (Germany)</p> <p>MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: FIVE-YEARS DRUG SURVIVAL IN RENAL AND NON-RENAL INVOLVEMENT Presenter Giulio Olivieri (Italy)</p> <p>MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: FIVE-YEARS DRUG SURVIVAL IN RENAL AND NON-RENAL INVOLVEMENT. Giulio Olivieri (Italy)</p>	<p>Photosensitivity: mechanisms and treatment. J Kahlenberg (USA)</p> <p>PREDICTORS OF MUSCULOSKELETAL AND MUCOCUTANEOUS RESPONSE TO BELIMUMAB IN PATIENTS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM A LARGE MULTICENTRIC NATIONWIDE COHORT. Roberto Depascale (Italy)</p> <p>CAPILLARY SCLERODERMA PATTERN AND DISEASE DAMAGE IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: IMPORTANT LESSONS FROM LONGITUDINAL FOLLOW-UP. Dieneke Schonenberg-Meinema (Netherlands)</p> <p>SENESCENT PROGENITOR CELLS IN THE SKIN OF PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS. Sarah Pringle (Netherlands)</p>	<p>Panel Discussion &amp; Poll</p> <p>SIGNIFICANT INHIBITION OF THE TLR7/CXCL10 SIGNALING AXIS BY LMWF5A IN MONOCYTIC LINEAGES; IMPLICATIONS FOR COVID-19 AND LUPUS NEPHRITIS. Gregory Thomas (United States of America)</p> <p>INCIDENCE OF SARS-COV-2 IN PATIENTS WITH RHEUMATIC DISEASES ON HYDROXYCHLOROQUINE. Mikel Jordhani (Albania)</p>	<p>Panel Discussion &amp; Poll</p> <p>PREVELANCE OF NON- CRITERIA ANTIPHOSPHOLIPID ANIBODIES IN PATIENTS WITH PRIMARY ANTYPHOSPHOLIPID SYNDROME. Magdalena Dryglewska (Poland)</p> <p>AUTOIMMUNE DISEASES AND PREGNANCY OUTCOMES: A RETROSPECTIVE STUDY. Gabriel J. Tobón (Colombia)</p> <p>THE EMERGING ROLE OF COMPLEMENT C5 IN THE DEVELOPMENT OF PRIMARY SJÖGREN'S SYNDROME. Haijun Ma (China)</p>
---	--	--	---	--


CEST (UTC+2 Paris, Amsterdam, Berlin) 19:15–20:15 hours / EDT (UTC-4 New York, Montreal) 13:15 – 14:15 hours/ CST (UTC+8 Beijing, Manila, Perth) 01:15 – 02:15 hours

<p><b>Meet the Professor 7</b></p> <p><b>What should we measure in clinical practice in SLE patients?</b></p> <p>Americas: MF Ugarte-Gil (Peru)</p>	<p><b>Meet the Professor 8</b></p> <p><b>Molecules in the development in SLE therapy</b></p> <p>Americas: D Wallace (USA)</p>	<p><b>Workshop 7</b></p> <p><b>Management of lupus pregnancies</b></p> <p>Angela Tincani (Italy)</p>	<p><b>Workshop 8</b></p> <p><b>Cardio-pulmonary manifestations</b></p> <p>Americas: M Petri (USA)</p>	<p><b>Meet the Professor (CORA) 4</b></p> <p><b>Cannabis: a friend or a foe?</b></p> <p>Piercarlo Sarzi-Puttini (Italy)</p>
---	---	--	---	---

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

**Saturday, 9 October 2021**

Hall 1	Hall 2	Hall 3	Hall 4	Hall 5
CEST (UTC+2 Paris, Amsterdam, Berlin) 09:30–10:30 hours / EDT (UTC-4 New York, Montreal) 3:30 – 4:30 hours / CST (UTC+8 Beijing, Manila, Perth) 15:30 – 16:30 hours				
<b>Meet the Professor 9</b> <b>The standard of care in SLE</b> M. Govoni, Ferrara (Italy) 	<b>Meet the Professor 10</b> <b>Why is everything autoimmune until proven otherwise?</b> Y Shoenfeld (Israel) 	<b>Workshop 9</b> <b>Neuropsychiatric lupus</b> DT. Boumpas (Greece) 	<b>Workshop 10</b> <b>Musculoskeletal manifestations in SLE</b> L Iaccarino (Italy) 	<b>Meet professor (CORA) 5</b> <b>Systemic sclerosis: what is new?</b> R. Giacomelli (Italy) 
CEST (UTC+2 Paris, Amsterdam, Berlin) 10:30–12:00 hours / EDT (UTC-4 New York, Montreal) 4:30 – 6:00 hours / CST (UTC+8 Beijing, Manila, Perth) 16:30 – 18:00 hours				
<b>Plenary 5: Is it safe to withdraw a low-dose-glucocorticoid in SLE patients in remission?</b> Chair: R Cervera (Spain) Introduction: R Cervera Yes G. Ruiz-Irastorza (Spain) vs. No Z. Amoura (France) Panel discussion Summary: R. Cervera Chair: R Cervera (Spain)  				
CEST (UTC+2 Paris, Amsterdam, Berlin) 12:00–12:30 hours / EDT (UTC-4 New York, Montreal) 6:00 – 6:30 hours / CST (UTC+8 Beijing, Manila, Perth) 18:00 – 18:30 hours				
Networking Break, Exhibition & Poster Viewing + Short Oral Discussions				
LIVE E-POSTER DISCUSSION: SLE 17 Chair: Alessandra Bortoluzzi (Italy) 	LIVE E-POSTER DISCUSSION: SLE 18 Chair: Isabell Haase (Germany) 			
CEST (UTC+2 Paris, Amsterdam, Berlin) 12:30–14:30 hours / EDT (UTC-4 New York, Montreal) 6:30 – 8:30 hours / CST (UTC+8 Beijing, Manila, Perth) 18:30 – 20:30 hours				
<b>Parallel 15 SLE</b> <b>New clues in LN pathogenesis</b> Chair: A Davidson (USA), T. Dörner, Berlin (Germany) 1. Pseudo-antiviral immunity drives LN: is IFN the right target even for LN. HJ Anders (Germany) 2. The importance of immune and local factors in the expression of kidney injury G Tsokos (USA)	<b>Parallel 16 SLE</b> <b>Difficult-to-manage- SLE manifestations</b> Chairs: C. Vasconcelos, Porto (Portugal), GS Alarcón (USA) 1. Refractory SLE manifestations. Dario Roccatello; Italy 2. Fatigue in SLE. Matthias Schneider, Germany 3. Autoinflammatory manifestations in SLE Raquel Faria, (Portugal)	<b>Parallel 9 (CORA)</b> <b>Rheumatoid arthritis</b> Chair: F Atzeni (Italy) Can Pain and Fatigue in RA patient. Are small molecules better than biologics?  YES: small molecules better P Sarzi-Puttini (Italy) NO: biologics better D Aletaha (Austria)	<b>Parallel 10 (CORA)</b> <b>Autoimmunity and autoinflammation</b> Chair: G Nagy (Hungary) Can autoimmunity and autoinflammation be separated?  YES: there are two endpoints, phenotypic differences: Z Szekanecz (Hungary) NO: there is no such distinction: C Chizzolini (Switzerland)	

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>3. The role of pentraxin in LN – more than a biomarker? M Gatto (Italy)</p> <p>4. A NEUTROPHIL DEGRANULATION SIGNATURE IDENTIFIES PROLIFERATIVE LUPUS NEPHRITIS. Andrea Fava (United States of America)</p> <p>5. CLINICAL AND GENETIC RISK FACTORS ASSOCIATED WITH THE PRESENCE OF LUPUS NEPHRITIS. Jung min Shin (Korea, Republic of)</p> <p style="text-align: right;"><b>SEMI LIVE</b></p>	<p>4. A NEUTROPHIL DEGRANULATION SIGNATURE IDENTIFIES PROLIFERATIVE LUPUS NEPHRITIS. Andrea Fava (United States of America)</p> <p>5. CLINICAL AND GENETIC RISK FACTORS ASSOCIATED WITH THE PRESENCE OF LUPUS NEPHRITIS. Jung min Shin (Korea, Republic of)</p> <p style="text-align: right;"><b>SEMI LIVE</b></p>	<p>Panel Discussion &amp; Poll</p> <p>1. COMPARISON OF RHEUMATOID ARTHRITIS PATIENTS RECENTLY SWITCHED TO JAK INHIBITOR THERAPY IN THE US AND EU5: COMORBIDITY AND SWITCH PATTERN ANALYSIS FROM PATIENT CHART AUDIT. Maxine Yarnall (USA)</p> <p>2. A NEW APPROACH TO INTERLEUKINE 8 IN RHEUMATOID ARTHRITIS - THE ASSOCIATION WITH ACPA AND DISEASE ACTIVITY. Aleksandra Starzyk (Poland)</p> <p style="text-align: right;"><b>SEMI LIVE</b> </p>	<p>Panel Discussion &amp; Poll</p> <p>1. POLYAUTOIMMUNITY IS PRESENT IN A THIRD OF LUPUS PATIENTS IN COLOMBIA - ITS ASSOCIATED FACTORS. Pedro Santos-Moreno (Colombia)</p> <p>2. INTERFERON INFLAMMATION IN A CASE WITH PAMI SYNDROME AND POSSIBLE RELATIONSHIP WITH GENE EXPRESSION. Alessia Pin (Italy)</p> <p>3. TEARS PROTEOMIC PROFILING OF BLAU SYNDROME FOR IDENTIFICATION OF POTENTIAL DISEASE BIOMARKERS. Paola Galozzi (Italy)</p> <p style="text-align: right;"><b>SEMI LIVE</b> </p>
---	--	---	---

CEST (UTC+2 Paris, Amsterdam, Berlin) 14:30–15:30 hours / EDT (UTC-4 New York, Montreal) 8:30 – 9:30 hours / CST (UTC+8 Beijing, Manila, Perth) 20:30 – 21:30 hours

Networking Break, Exhibition & Poster Viewing + Short Oral Discussions

<p>LIVE E-POSTER DISCUSSION: SLE 19  </p> <p>Chair: Fulvia Ceccarelli (Italy)</p>	<p>LIVE E-POSTER DISCUSSION: SLE 21  </p> <p>Chair: Luis Ines (Portugal)</p>	<p>LIVE E-POSTER DISCUSSION: SLE 22  </p> <p>Chair: Alexandre Voskuyl (Netherlands)</p>
---	--	---

CEST (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours / EDT (UTC-4 New York, Montreal) 9:30 – 11:30 hours / CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

<p><b>Parallel 17 SLE</b>  <b>Management of SLE: what are we missing?</b>          Chairs: D. Boumpas (Greece), D Wallace (USA)</p> <ol style="list-style-type: none"> <li>Lupus in 2030: Successes and Challenges. David Wofsy (USA)</li> <li>Who cares? Quality of Care in SLE. Anna Kernder-Stupnanek (Germany)</li> <li>Can biologics improve the quality of life in SLE patients? I Parodis (Sweden)</li> <li>PROGNOSIS OF PATIENTS WITH PROLIFERATIVE LUPUS NEPHRITIS WHO DISCONTINUED IMMUNOSUPPRESSIVE</li> </ol>	<p><b>Parallel 18 SLE</b>  <b>Pregnancy</b>          Chairs: A Tincani (Italy), R Fischer-Betz (Germany)</p> <ol style="list-style-type: none"> <li>Pre-pregnancy counselling in women with SLE. Laura Andreoli (Italy)</li> <li>Can we predict and prevent pregnancy complications in patients with lupus and APS? Jane Salmon (USA)</li> <li>Positing the innate immune system at heart of the matter in neonatal lupus and application to new management strategies. Jill Buyon, USA</li> </ol>	<p><b>Parallel 11 (CORA)</b>  <b>Spondylarthritis</b>          Chair: P Sarzi-Puttini (Italy)</p> <p>Psoriatic arthritis joints or skin: which drives the treatment??</p> <p>Joints. Ian Bruce (UK)</p> <p>Skin. G Girolomoni (Italy)</p> <p>Panel Discussion &amp; Poll</p> <ol style="list-style-type: none"> <li>SECUKINUMAB DRUG SURVIVAL IN PSORIASIS AND PSORIATIC ARTHRITIS PATIENTS: A 24-MONTH REAL-LIFE STUDY. Augusta Ortolan (Italy)</li> </ol>	<p><b>Parallel 12 (CORA)</b>  <b>Vasculitis</b>          Chair: F Schiavon (Italy)</p> <p>Vasculitis: Is GCA and Takayasu the same?</p> <p>YES: the same. R Luqmani (UK)</p> <p>NO: differences between GCA-TA.</p> <p>C Salvarani (Italy)</p> <p>Panel Discussion &amp; Poll</p> <ol style="list-style-type: none"> <li>LARGE VESSEL- GIANT CELL ARTERITIS: A DIAGNOSTIC CHALLENGE. Francesca Regola (Italy)</li> <li>INCIDENCE OF CANCER IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS:</li> </ol>
---	--	---	---

Legend

Plenary session	Parallel session (Lupus)	Parallel session (CORA)	Industry session	Workshop	Meet the Professor (SLE)	Meet the Professor (CORA)
-----------------	--------------------------	-------------------------	------------------	----------	--------------------------	---------------------------

<p>THERAPY AFTER REMISSION ACHIEVEMENT. Margherita Zen (Italy)</p> <p>5. DERIVATION AND INDEPENDENT VALIDATION OF THE LUPUS ARTHRITIS AND MUSCULOSKELETAL DISEASE ACTIVITY SCORE (LAMDA): A MORE SENSITIVE, SPECIFIC AND RESPONSIVE TOOL FOR LUPUS ARTHRITIS. Edward M. Vital (United Kingdom)</p> <p>6. EASY-BILAG: A TOOL TO INCORPORATE BILAG-2004 DISEASE ACTIVITY ASSESSMENT INTO ROUTINE SLE CLINICAL CARE. Lucy M. Carter (United Kingdom)</p> <p style="text-align: right;"><b>SEMILIVE</b></p>	<p>4. COMBINATION OF LOW DOSE ASPIRIN AND HYDROXYCHLOROQUINE IS BENEFICIAL IN SLE PREGNANCIES WITH HIGH RISK FOR PRE-ECLAMPSIA. Isabell Haase (Germany)</p> <p>5. THE USE OF BELIMUMAB DURING PREGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. Francesca Crisafulli (Italy)</p> <p>6. PHYSICIAN'S OPINION AND OUTCOME OF PREGNANCIES: PRELIMINARY RESULTS FROM THE FRENCH MULTICENTRE PROSPECTIVE GR2 STUDY. Maddalena Larosa (Italy)</p> <p style="text-align: right;"><b>SEMILIVE</b></p>	<p>2. DECREASED PERCENTAGES OF CIRCULATING PLASMA BLASTS, T FOLLICULAR HELPER CELLS AND CXCR5+ TH17 CELLS ASSOCIATE WITH SECUKINUMAB-INDUCED REMISSION IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS. Athanasios Mavropoulos (Greece)</p> <p style="text-align: right;"><b>SEMILIVE</b> </p>	<p>A SINGLE CENTER STUDY. Roberto Padoan (Italy)</p> <p>3. BEHCET'S DISEASE IN DIFFERENT ETHNIC GROUPS. Regina G. Goloeva (Russian Federation)</p> <p style="text-align: right;"><b>SEMILIVE</b> </p>
---	--	--	--

CEST (UTC+2 Paris, Amsterdam, Berlin) 17:30–19:00 hours / EDT (UTC-4 New York, Montreal) 11:30 – 13:00 hours / CST (UTC+8 Beijing, Manila, Perth) 23:30 – 01:00 hours

**Plenary 6: When should targeted therapies be used in the treatment of lupus nephritis?**

Chair: F. Houssiau (Belgium)  
 Introduction: F. Houssiau (Belgium)  
 Early in the disease course. Maria Dall’Era, USA vs. Only in refractory patients. BH Rovin, USA  
 Panel discussion  
 Summary: F. Houssiau (Belgium)

**Congress Roundup Session (LIVE)**

Andrea Doria, Italy

